Valneva Announces Formation of Scientific Advisory Board
29 Juillet 2019 - 05:51PM
Valneva Announces Formation of Scientific
Advisory Board
Saint Herblain (France), July 29,
2019 – Valneva SE (“Valneva” or “the Company”), a biotech
company developing and commercializing vaccines for infectious
diseases with major unmet needs, today announced the formation of a
Scientific Advisory Board (“SAB”) as part of the evolution of its
governance structure.
The newly formed SAB will consist of
distinguished academic and industry professionals who will provide
the Company with guidance and expert advice on Research &
Development (“R&D”) strategies. The SAB remit will also include
program execution considerations in the framework of innovation,
market dynamics and trends.
Former Valneva Supervisory Board members, Dr.
Ralf Clemens, MD, Ph.D. and Dr. Alain Munoz, MD, Ph.D., will join
the SAB. Both have a deep understanding of the Company after
serving on its Supervisory Board for many years. Dr. Clemens will
chair the SAB.
Dr. Clemens commented, “I am pleased that
Valneva has decided to establish a SAB and to chair this important
group. Getting external advice from experts with various
backgrounds and competencies is especially important at this stage
of the company where two major, promising assets have entered late
stage development and the early stage development pipeline is
building up. I am also pleased that Dr. Munoz has agreed to join
the SAB and to bring in his experience in pharmaceutical
development and deep understanding of the company.”
Additional permanent members, complemented by
ad-hoc members with strong expertise in specific areas, will join
the SAB
Dr. Clemens previously headed vaccine
development at GSK, Novartis and Takeda. He advises and supports
several very significant organizations, including the Bill &
Melinda Gates Foundation and the GHIT Fund and is Member of the
Board of Trustees of the International Vaccine Institute IVI. Over
his years in the industry, he has led the clinical development of
more than 25 different vaccines globally and published extensively
in the fields of vaccines, immunization and tropical medicine.
Dr. Munoz previously served as SVP for
international development at Sanofi and as SVP of the
pharmaceutical division at Fournier Laboratories. Under his
leadership, several important drugs, such as Plavix or Tricor, were
brought from discovery to market. He serves on several boards,
including Hybrigenics SA, OxThera AB and Zealand Pharma A/S.
It is anticipated that the new SAB will be fully
operational by the end of 2019.
About Valneva SE
Valneva is a biotech company developing and
commercializing vaccines for infectious diseases with major unmet
needs. Valneva’s portfolio includes two commercial vaccines for
travelers: IXIARO®/JESPECT® indicated for the prevention of
Japanese encephalitis and DUKORAL® indicated for the prevention of
cholera and, in some countries, prevention of diarrhea caused by
ETEC. The Company has various clinical vaccines in development
including a unique vaccine against Lyme disease. Valneva has
operations in Austria, Sweden, the United Kingdom, France, Canada
and the US with approximately 480 employees. More information is
available at www.valneva.com.
Valneva
Investor and Media ContactsLaetitia
Bachelot-FontaineGlobal Head of Investor Relations & Corporate
CommunicationsM +33 (0)6 4516 7099investors@valneva.com |
Teresa
PinzolitsCorporate Communications SpecialistT +43 (0)1 20620
1116communications@valneva.com |
Forward-Looking Statements
This press release contains certain
forward-looking statements relating to the business of Valneva,
including with respect to the progress, timing and completion of
research, development and clinical trials for product candidates,
the ability to manufacture, market, commercialize and achieve
market acceptance for product candidates, the ability to protect
intellectual property and operate the business without infringing
on the intellectual property rights of others, estimates for future
performance and estimates regarding anticipated operating losses,
future revenues, capital requirements and needs for additional
financing. In addition, even if the actual results or development
of Valneva are consistent with the forward-looking statements
contained in this press release, those results or developments of
Valneva may not be indicative of their in the future. In some
cases, you can identify forward-looking statements by words such as
"could," "should," "may," "expects," "anticipates," "believes,"
"intends," "estimates," "aims," "targets," or similar words. These
forward-looking statements are based largely on the current
expectations of Valneva as of the date of this press release and
are subject to a number of known and unknown risks and
uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from any
future results, performance or achievement expressed or implied by
these forward-looking statements. In particular, the expectations
of Valneva could be affected by, among other things, uncertainties
involved in the development and manufacture of vaccines, unexpected
clinical trial results, unexpected regulatory actions or delays,
competition in general, currency fluctuations, the impact of the
global and European credit crisis, and the ability to obtain or
maintain patent or other proprietary intellectual property
protection. In light of these risks and uncertainties, there can be
no assurance that the forward-looking statements made during this
presentation will in fact be realized. Valneva is providing the
information in these materials as of this press release, and
disclaim any intention or obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events, or otherwise.